Exploring blood markers and their impact on diabetic peripheral neuropathy
The Effect of Related Blood Markers on Diabetic Peripheral Neuropathy
This study is testing whether certain blood markers can help us understand and improve diabetic peripheral neuropathy in people with diabetes by giving them either diabetes or cholesterol medications.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 1400 (estimated) |
| Sex | All |
| Sponsor | First Affiliated Hospital of Wenzhou Medical University Academic / other |
| Locations | 1 site (Wenzhou, Zhejiang) |
| Trial ID | NCT06041399 on ClinicalTrials.gov |
What this trial studies
This interventional clinical trial aims to investigate the relationship between specific blood markers and diabetic peripheral neuropathy in a randomized, double-blind, placebo-controlled format. Conducted across multiple centers, the study will enroll over 1000 participants who have undergone nerve conduction examinations. Data will be collected from electronic health records, including demographic details, blood biochemical markers, and electromyography results. Participants will receive either hypoglycemic agents or lipid-lowering drugs as part of the intervention.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with diabetic peripheral neuropathy who have undergone nerve conduction examinations.
Not a fit: Patients with severe comorbid conditions, such as chronic liver disease or malignancies, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of diabetic peripheral neuropathy through targeted blood marker analysis.
How similar studies have performed: While there have been studies exploring blood markers in relation to diabetic conditions, this specific approach is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients who had undergone nerve conduction examination by electromyography(EMG). Exclusion Criteria: * pregnancy and lactation; chronic liver disease, kidney disease, arrhythmias, malignant diseases, severe respiratory diseases, heart failure, and acute infections; * patients with alcohol abuse; history of Autoimmune liver disease, liver disease or abnormal liver function at baseline; * parathyroid diseases (including hyperthyroidism and hypothyroidism); * pancreatitis, pancreatectomy or any transplant; * patients with malignancy and any serious concomitant disease limit the existence of life expectancy
Where this trial is running
Wenzhou, Zhejiang
- First Affiliated Hospital of Wenzhou Medical University — Wenzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Binbin Deng, Doctor
- Email: dbinbin@aliyun.com
- Phone: 86-13695720610
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.